These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cost-effectiveness of iso- versus low-osmolality contrast media in outpatients with high risk of contrast medium-induced nephropathy. Chicaíza-Becerra LA, García-Molina M, Gamboa Ó. Biomedica; 2012 Jun; 32(2):182-8. PubMed ID: 23242291 [Abstract] [Full Text] [Related]
4. Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Lundkvist J. Am Heart J; 2005 Feb; 149(2):298-303. PubMed ID: 15846268 [Abstract] [Full Text] [Related]
6. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention. Nie B, Cheng WJ, Li YF, Cao Z, Yang Q, Zhao YX, Guo YH, Zhou YJ. Catheter Cardiovasc Interv; 2008 Dec 01; 72(7):958-65. PubMed ID: 19021282 [Abstract] [Full Text] [Related]
9. Economic impact of contrast-induced acute kidney injury associated with invasive cardiology: role of iso-osmolar contrast media in Germany, Italy, Poland, and Spain. De Francesco M, Ronco C, Wacinski PJ, Wessely R, Hernández F, Lamotte M. J Med Econ; 2016 Dec 01; 19(2):158-68. PubMed ID: 26451530 [Abstract] [Full Text] [Related]